Circulation · 2009 · 18 citations · 0 references
MedicineGeneticsPharmacologyClinical PharmacologyPharmacogeneticsPharmacogenomicsCardiac Risk AssessmentCardiovascular DiseaseCardiovascular Drug SafetyCardiovascular PharmacogenomicsGenetic RiskPharmacogenomics In CardiologyAdverse Cardiovascular Drug EventsClopidogrel Pharmacogenetic TestingCyp2c19 Drug MetabolismCyp2c19 GenotypeCyp2c19 PharmacogeneticsCyp2c19-guided Antiplatelet TherapyCyp2c9 GenotypingCytochrome P450 2C19 Genotyping
Introduction: Several studies have recently evaluated the relationship between CYP2C19 variants and risk of adverse cardiovascular (CV) events in the setting of clopidogrel treatment. However, risk...